[{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"AAZ","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for AAZ

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The paper reveals DLX-1—a new compound inspired by the chemical structures of common psychedelic substances that demonstrates sustained antidepressant effects but without hallucinogenic properties.

                          Brand Name : DLX-1

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 28, 2021

                          Lead Product(s) : AAZ

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank